Back to list BIORCHESTRA receives Citation from the Korean Minister of Trade, Industry, and Energy A leader in creating jobs through the advancement of RNA-based therapeuticsA contributor to a high…
Back to list BIORCHESTRA Announces that its Proprietary Compound, BMD-001, Reduces Amyloid-β and Tau Inflammatory Symptoms in Primate Models for Alzheimer's Disease at the RNA Leaders USA Conference Boston, MA,…
Back to list BIORCHESTRA appointed Dr. Gabriel Helmlinger (Ph.D., DABT) as Head of Translational and Clinical Pharmacology, Toxicology BIORCHESTRA, headquartered in Daejeon, South Korea, appointed Dr. Gabriel Helmlinger (Ph.D., D.A.B.T.) as Vice-President, Head…